指南与共识泌尿生殖MRUS

基于证据的指南推荐:多参数磁共振成像在诊断临床显著前列腺癌中的应用——安大略癌症治疗中心更新的临床实践指南

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline.
指南 / 共识 · Can Urol Assoc J · 2022-01-01

该临床实践指南基于系统评价,评估多参数磁共振成像(mpMRI)在活检初治及既往经直肠超声引导系统活检(TRUS-SB)阴性且风险升高的男性中诊断临床显著前列腺癌(csPCa)的作用。指南推荐:对活检初治且适合治愈性治疗的高风险患者,活检前应行mpMRI;mpMRI阳性时靶向活检(TB)与TRUS-SB联合以最大化检出csPCa;mpMRI阴性时可在共同决策下考虑放弃活检。对既往TRUS-SB阴性且高风险患者,应行mpMRI;阳性时行靶向活检,可考虑同期TRUS-SB;阴性时可在共同决策下考虑放弃TRUS-SB。mpMRI应按照当前PI-RADS指南执行和解读。

要点

  • 活检初治且适合治愈性治疗的高风险患者,推荐活检前行mpMRI。
  • mpMRI阳性时,推荐靶向活检与TRUS-SB联合以最大化检出csPCa。
  • mpMRI阴性时,可在共同决策和随访下考虑放弃活检。

核心结论

  • 对活检初治或既往TRUS-SB阴性且风险升高的男性,mpMRI用于诊断csPCa有明确推荐路径,且mpMRI须按当前PI-RADS指南执行和解读。

研究设计与样本

  • 临床实践指南,基于系统评价,检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials至2020年9月,并经过内部和外部评审。

诊断标准与关键数值

  • 推荐1:对活检初治、疑似临床局限前列腺癌且适合治愈性治疗的高风险患者,推荐活检前行mpMRI。
  • 推荐1:若mpMRI阳性,应联合行mpMRI靶向活检(TB)与TRUS-SB以最大化检出csPCa;若mpMRI阴性,可在与患者讨论风险获益并共同决策及持续随访下考虑放弃活检。
  • 推荐2:对既往TRUS-SB阴性且考虑治愈性治疗的高风险患者,应行mpMRI;若阳性,应行靶向活检,可根据患者风险特征和距前次TRUS-SB时间考虑同期TRUS-SB;若阴性,仅在讨论风险获益并共同决策及持续随访下考虑放弃TRUS-SB。
  • 推荐3:mpMRI应按照当前前列腺影像报告和数据系统(PI-RADS)指南执行和解读。

临床应用与阅片要点

  • 活检初治的高风险患者,活检前应行mpMRI,并按PI-RADS指南解读。
  • mpMRI阳性时,靶向活检应与TRUS-SB联合进行,以最大化csPCa检出。
  • mpMRI阴性时,可在与患者共同决策并持续随访的前提下考虑放弃活检。
  • 既往TRUS-SB阴性且高风险者应行mpMRI;阳性时行靶向活检,可考虑同期TRUS-SB。
  • 既往TRUS-SB阴性者若mpMRI阴性,仅在共同决策和持续随访下考虑放弃TRUS-SB。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: This clinical practice guideline is based on a systematic review to assess the use of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis of clinically significant prostate cancer (csPCa) for biopsy-naive men and men with a prior negative transrectal ultrasound-guided systematic biopsy (TRUS-SB) at elevated risk.

METHODS: The methods of the clinical practice guideline included searches to September of 2020 of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. Internal and external reviews were conducted.

RESULTS: The recommendations are:Recommendation 1: For biopsy-naive patients at elevated risk of csPCa, mpMRI is recommended prior to biopsy in patients who are candidates for curative management with suspected clinically localized prostate cancer.- If the mpMRI is positive, mpMRI-targeted biopsy (TB) and TRUS-SB should be performed together to maximize detection of csPCa.- If the mpMRI is negative, consider forgoing any biopsy after discussion of the risks and benefits with the patient as part of shared decision-making and ongoing followup.Recommendation 2: In patients who had a prior negative TRUS-SB and demonstrate a high risk of having csPCa in whom curative management is being considered:- mpMRI should be performed.- If the mpMRI is positive, targeted biopsy should be performed. Concomitant TRUS-SB can be considered depending on the patient's risk profile and time since prior TRUS-SB biopsy.- If the mpMRI is negative, consider forgoing a TRUS-SB only after discussion of the risks and benefits with the patient as part of shared decision-making and ongoing followup.Recommendation 3: mpMRI should be performed and interpreted in compliance with the current Prostate Imaging Reporting & Data System (PI-RADS) guidelines.

来源:Can Urol Assoc J,查看原文。版权归原作者所有。

引用

  1. Haider MA, Brown J, Chin JLK, et al. Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline. Can Urol Assoc J. 2022. PMID: 35133265. doi:10.5489/cuaj.7425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。